Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Stock Holdings Reduced by Thrivent Financial for Lutherans

Thrivent Financial for Lutherans lessened its stake in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 4.9% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 110,389 shares of the biotechnology company’s stock after selling 5,734 shares during the quarter. Thrivent Financial for Lutherans’ holdings in Ironwood Pharmaceuticals were worth $455,000 as of its most recent filing with the SEC.

Several other large investors also recently made changes to their positions in IRWD. Price T Rowe Associates Inc. MD boosted its stake in shares of Ironwood Pharmaceuticals by 6.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 85,577 shares of the biotechnology company’s stock worth $746,000 after acquiring an additional 4,993 shares in the last quarter. GAMMA Investing LLC raised its holdings in Ironwood Pharmaceuticals by 344.1% in the 2nd quarter. GAMMA Investing LLC now owns 10,526 shares of the biotechnology company’s stock valued at $69,000 after acquiring an additional 8,156 shares in the last quarter. CWM LLC raised its holdings in Ironwood Pharmaceuticals by 55.1% in the 2nd quarter. CWM LLC now owns 6,600 shares of the biotechnology company’s stock valued at $43,000 after acquiring an additional 2,345 shares in the last quarter. SG Americas Securities LLC raised its holdings in Ironwood Pharmaceuticals by 78.9% in the 2nd quarter. SG Americas Securities LLC now owns 18,769 shares of the biotechnology company’s stock valued at $122,000 after acquiring an additional 8,277 shares in the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. raised its holdings in shares of Ironwood Pharmaceuticals by 7.3% in the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 59,967 shares of the biotechnology company’s stock worth $391,000 after buying an additional 4,100 shares in the last quarter.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the company. Craig Hallum dropped their target price on Ironwood Pharmaceuticals from $14.00 to $10.00 and set a “buy” rating for the company in a report on Friday, August 9th. Wells Fargo & Company decreased their price objective on Ironwood Pharmaceuticals from $14.00 to $12.00 and set an “overweight” rating on the stock in a research report on Friday, August 9th. Leerink Partnrs upgraded Ironwood Pharmaceuticals to a “hold” rating in a research report on Monday, September 9th. Capital One Financial downgraded Ironwood Pharmaceuticals from an “overweight” rating to an “equal weight” rating and dropped their price objective for the stock from $12.00 to $4.00 in a research note on Thursday, August 8th. Finally, StockNews.com downgraded Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, November 12th. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $10.40.

Ironwood Pharmaceuticals Stock Performance

Ironwood Pharmaceuticals stock opened at $3.34 on Friday. Ironwood Pharmaceuticals, Inc. has a 52 week low of $3.26 and a 52 week high of $15.70. The stock has a market capitalization of $534.50 million, a P/E ratio of -111.33 and a beta of 0.41. The stock has a 50-day simple moving average of $4.07 and a 200 day simple moving average of $5.11.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.07). Ironwood Pharmaceuticals had a negative return on equity of 0.96% and a negative net margin of 0.65%. The firm had revenue of $91.60 million for the quarter, compared to the consensus estimate of $91.22 million. During the same quarter in the prior year, the firm earned $0.12 EPS. The company’s revenue was down 19.4% on a year-over-year basis. Research analysts forecast that Ironwood Pharmaceuticals, Inc. will post 0.08 earnings per share for the current year.

Insider Activity

In other news, CFO Sravan Kumar Emany sold 11,001 shares of the company’s stock in a transaction on Monday, November 18th. The shares were sold at an average price of $4.08, for a total transaction of $44,884.08. Following the completion of the transaction, the chief financial officer now directly owns 309,572 shares in the company, valued at approximately $1,263,053.76. This represents a 3.43 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 12.90% of the stock is owned by company insiders.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.